Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes
Open accessThe DOI matches its Crossref record; 228 of the 230 references it cites were found in a registry or an index.
Abstract
Post-transplant diabetes mellitus (PTDM) is a frequent consequence of solid organ transplantation. PTDM has been associated with greater mortality and increased infections in different transplant groups using different diagnostic criteria. An international consensus panel recommended a consistent set of guidelines in 2003 based on American Diabetes Association glucose criteria but did not exclude the immediate post-transplant hospitalization when many patients receive large doses of corticosteroids. Greater glucose monitoring during all hospitalizations has revealed significant glucose intolerance in the majority of recipients immediately after transplant. As a result, the international consensus panel reviewed its earlier guidelines and recommended delaying screening and diagnosis of PTDM until the recipient is on stable doses of immunosuppression after discharge from initial transplant hospitalization. The group cautioned that whereas hemoglobin A1C has been adopted as a diagnostic criterion by many, it is not reliable as the sole diabetes screening method during the first year after transplant. Risk factors for PTDM include many of the immunosuppressant medications themselves as well as those for type 2 diabetes. The provider managing diabetes and associated dyslipidemia and hypertension after transplant must be careful of the greater risk for drug-drug interactions and infections with immunosuppressant medications. Treatment goals and therapies must consider the greater risk for fluctuating and reduced kidney function, which can cause hypoglycemia. Research is actively focused on strategies to prevent PTDM, but until strategies are found, it is imperative that immunosuppression regimens are chosen based on their evidence to prolong graft survival, not to avoid PTDM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The clinical importance of PTDM lies in its unquestionable impact as a signi fi cant risk factor for cardiovascular disease and chronic kidney disease in solid-organ transplantation (137).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [137]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The clinical importance of PTDM lies in its impact as a significant risk factor for cardiovascular disease and chronic kidney disease in solid-organ transplantation (137).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Classification and Diagnosis of Diabetes
Fajans, S. S. (1990) · Medical Entomology and Zoology · Cited by 2,359
Cited by
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
“Several terms are used in the literature to describe the presence of diabetes following organ transplantation (142).”
Background2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
“Several terms are used in the literature to describe the presence of diabetes following organ transplantation (85).”
Background2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
“Several terms areused in the literature to describe the presence of diabetes following organ transplantation (113).”
Background2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,433
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s002 · Cited by 2,086
2. Diagnosis and classification of diabetes: standards of care in diabetes-2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s002 · Cited by 1,393
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s002 · Cited by 473
Lactate Limits T Cell Proliferation via the NAD(H) Redox State
Quinn, W. J., Jiao, J., TeSlaa, T., Stadanlick, J., Wang, Z., Wang, L., Akimova, T., Angelin, A., Schäfer, P. M., Cully, M. D., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108500 · Cited by 362
“In light of substantial toxicity from conventional immunosuppressive drugs (Fishman, 2007; Naesens et al., 2009; Shivaswamy et al., 2016), it is conceivable to consider lactate supplementation and dietary serine restriction to perhaps allow lower dosing in conventional immunosuppressive therapies.”
Rangaswami, J., Mathew, R. O., Parasuraman, R., Tantisattamo, E., Lubetzky, M., Rao, S., Yaqub, M. S., Birdwell, K. A., Bennett, W., Dalal, P., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz053 · Cited by 221
Wang, W., Tan, J., Nima, L., Sang, Y., Cai, X., & Xue, H. (2022) · Food Chemistry: X · doi:10.1016/j.fochx.2022.100414 · Cited by 158
Comprehensive Care of the Lung Transplant Patient
Adegunsoye, A., Strek, M. E., Garrity, E. R., Guzy, R. D., & Bag, R. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.10.001 · Cited by 132
“In suboptimal glycemic control, a more aggressive approach such as the use of an insulin pump may be beneficial.(80) Dietary and lifestyle modifications such as exercise and weight optimization and annual screening are performed as in the general population.”
BackgroundChen, N., Zhang, H., Zong, X., Li, S., Wang, J., Wang, Y., & Jin, M. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116750 · Cited by 118
Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
Hecking, M., Sharif, A., Eller, K., & Jenssen, T. G. (2020) · Transplant International · doi:10.1111/tri.13783 · Cited by 125
“Post-transplant diabetes mellitus (PTDM) [1,2] is a common and important complication after solid organ”
BackgroundThangavelu, T., Lyden, E., & Shivaswamy, V. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00786-1 · Cited by 96
Self-citationManagement of Recurrent and De Novo NAFLD/NASH After Liver Transplantation
Germani, G., Laryea, M., Rubbia-Brandt, L., Egawa, H., Burra, P., O'Grady, J., & Watt, K. D. (2019) · Transplantation · doi:10.1097/tp.0000000000002485 · Cited by 92
“Although it has not been shown to affect tacrolimus levels, its effect on gut transit may affect absorption and it is not recommended if the GFR is <40.(101)”
BackgroundPost-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment
Peláez-Jaramillo, M. J., Cárdenas-Mojica, A. A., Gaete, P. V., & Mendivil, C. O. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0374-8 · Cited by 89
“A 2-h post-OGTT plasma glucose level of \ 140 mg/dL (7.7 mmol/L) is considered to be normal, 140–199 mg/dL (7.7–11.1 mmol/L) is considered to be impaired glucose tolerance (IGT) and C 200 mg/dL (11.2 mmol/L) constitutes diabetes.”
BackgroundInfluentialThe Human Islet: Mini-Organ With Mega-Impact
Walker, J. T., Saunders, D. C., Briššová, M., & Powers, A. C. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab010 · Cited by 97
Sánchez-Fructuoso, A. I., Raba, A. B., Banegas‐Deras, E. J., Vigara, L. A., Valero, R., Esteve, A. F., Vega, L. L. C., Gavela, E., González, E., Coronado, P. S., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad007 · Cited by 82
“In KTRs, diabetes has been associated with a 2- to 4-fold increased risk of cardiac events, as well as infectious complications and lower patient survival [2, 4, 7, 8].”
The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients
Kukla, A., Hill, J., Merzkani, M., Bentall, A., Lorenz, E. C., Park, W. D., D’Costa, M., Kudva, Y. C., Stegall, M. D., & Shah, P. (2020) · Transplantation Direct · doi:10.1097/txd.0000000000000971 · Cited by 73
Kaundal, U., Bagai, U., & Rakha, A. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1403-0 · Cited by 79
Epidemiology of diabetes mellitus
Mekala, K. C., & Bertoni, A. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00004-6 · Cited by 97
Metabolic Consequences of Solid Organ Transplantation
Bhat, M., Usmani, S. E., Azhie, A., & Woo, M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa030 · Cited by 80
Butyric acid normalizes hyperglycemia caused by the tacrolimus-induced gut microbiota
Jiao, W., Zhang, Z., Xu, Y., Gong, L., Zhang, W., Tang, H. T., Zeng, S., Zhang, Q., Sun, Z., Liu, L., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15880 · Cited by 68
Tacrolimus- and sirolimus-induced human β cell dysfunction is reversible and preventable
Dai, C., Walker, J. T., Shostak, A., Padgett, A., Spears, E., Wisniewski, S., Poffenberger, G., Aramandla, R., Dean, E. D., Prasad, N., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.130770 · Cited by 64
Post-Transplantation Diabetes Mellitus
Ahmed, S. H., Biddle, K., Augustine, T., & Azmi, S. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00790-5 · Cited by 77
Torres, A., Hernández, D., Moreso, F., Serón, D., Burgos, M. D., Pallardó, L., Kanter, J., Corte, C. D., Rodríguez, M., Díaz, J. M., et al. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.07.009 · Cited by 64
“RT recipients with risk factors for type 2 diabetes most commonly develop PTDM after exposure to immunosuppressants.(2,10,11) These risk factors include age older than 45 years at the time of transplantation, overweight, obesity, and hypertriglyceridemia, a known marker of insulin resistance.”
BackgroundManagement of metabolic syndrome and cardiovascular risk after liver transplantation
Fatourou, E. M., & Tsochatzis, E. A. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30181-5 · Cited by 59
Current status of glucocorticoid usage in solid organ transplantation
Dashti‐Khavidaki, S., Saidi, R. F., & Lu, H. (2021) · World Journal of Transplantation · doi:10.5500/wjt.v11.i11.443 · Cited by 67
Metabolic Disorders with Kidney Transplant
Cohen, E., Korah, M. M., Callender, G. G., Aguiar, R. B. D., & Haakinson, D. J. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09310819 · Cited by 65
Liou, J.-H., Liu, Y.-M., & Chen, C.-H. (2018) · Transplantation Proceedings · doi:10.1016/j.transproceed.2018.03.087 · Cited by 55
Chewcharat, A., Prasitlumkum, N., Thongprayoon, C., Bathini, T. J., Medaura, J. A., Vallabhajosyula, S., & Cheungpasitporn, W. (2020) · Medical Sciences · doi:10.3390/medsci8040047 · Cited by 62
“In addition, approximately 15–30% of nondiabetic kidney transplant recipients develop new-onset diabetes after transplant [3–5], resulting in a high prevalence of kidney transplant recipients with preexisting and post-transplant diabetes mellitus (PTDM), ranging up to 74% depending on country, ethnicity, and criteria…”
New-onset diabetes after kidney transplantation: Incidence and associated factors
Gomes, V., Ferreira, F., Guerra, J. O., & Bugalho, M. J. (2018) · World Journal of Diabetes · doi:10.4239/wjd.v9.i7.132 · Cited by 53
Kim, D.-S., Yoon, Y.-I., Kim, B. K., Choudhury, A., Kulkarni, A., Park, J. Y., Kim, J., Sinn, D. H., Joo, D. J., Choi, Y., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10629-3 · Cited by 47
Courbebaisse, M., Bourmaud, A., Souberbielle, J., Sberro‐Soussan, R., Moal, V., Meur, Y. L., Kamar, N., Albano, L., Thierry, A., Dantal, J., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2022.12.007 · Cited by 48
Opałka, B., Żołnierczuk, M., & Grabowska, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216935 · Cited by 57
“It has been shown that taking CNIs is associated with an increased risk of hyperglycemia and diabetes [120,121].”
BackgroundLo, C., Jun, M., Badve, S. V., Pilmore, H., White, S. L., Hawley, C., Cass, A., Perkovic, V., & Zoungas, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009966.pub2 · Cited by 41
Ali, S. S., Alsharbaty, M. H. M., Al-Tohamy, R., Naji, G. A.-H., Elsamahy, T., Mahmoud, Y. A. ‐., Kornaros, M. E., & Sun, J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132986 · Cited by 50
Post-transplant diabetes mellitus following heart transplantation
Newman, J. D., Schlendorf, K. H., Cox, Z. L., ZALAWADIYA, S. K., Powers, A. C., Niswender, K. D., Shah, R. V., & Lindenfeld, J. M. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.07.011 · Cited by 49
Lemke, A. I., Brokmeier, H. M., Leung, S. B., Mara, K. C., Mour, G. K., Wadei, H. M., Hill, J. M., Stegall, M. D., Kudva, Y. C., Shah, P., et al. (2022) · Clinical Transplantation · doi:10.1111/ctr.14718 · Cited by 44
Lombardi, A., Gambardella, J., Du, X.-L., Sorriento, D., Mauro, M., Iaccarino, G., Trimarco, B., & Santulli, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-15283-y · Cited by 44
Management of diabetes mellitus in chronic kidney disease
Garla, V. V., Kanduri, S. R., Yanes-Cardozo, L. L., & Lien, L. F. (2019) · Minerva Endocrinology · doi:10.23736/s0391-1977.19.03015-3 · Cited by 46
Barra, J. M., Robino, R. A., Castro-Gutiérrez, R., Proia, J., Russ, H. A., & Ferreira, L. M. R. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114994 · Cited by 42
Chen, G., Gao, L., & Li, X. (2019) · Renal Failure · doi:10.1080/0886022x.2019.1611602 · Cited by 44
“Further, the common immunosuppressive choices after KTx also contribute to the burden of CVD risk factors: corticosteroids tend to promote metabolic syndrome due to their antimetabolic effects; cyclosporine is associated with hypertension and hyperlipidemia while tacrolimus is related with insulin resistance and postt…”
BackgroundPost-transplant Diabetes Mellitus in Kidney Transplant Recipients: A Multicenter Study
Malik, R. F., Jia, Y., Mansour, S. G., Reese, P. P., Hall, I. E., Alasfar, S., Doshi, M. D., Akalin, E., Bromberg, J. S., Harhay, M. N., et al. (2021) · Kidney360 · doi:10.34067/kid.0000862021 · Cited by 43
“Intravenous immunoglobulin 39 (9) 11 (6) Methylprednisolone 407 (91) 177 (95) Anti-thymocyte globulin (rabbit) 368 (83) 157 (84) Basiliximab 64 (14) 31 (17) Alemtuzumab 15 (3) 3 (2) Rituximab 9 (2) 1 (1) Experimental or other drug used for induction 7 (2) 2 (1)”
Lin, H., Yan, J., Yuan, L., Qi, B., Zhang, Z., Zhang, W., Ma, A., & Ding, F. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00742-4 · Cited by 44
Cochrane, R. W., Robino, R. A., Granger, B., Allen, E., Vaena, S. G., Romeo, M. J., de Cubas, A. A., Berto, S., & Ferreira, L. M. R. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101385 · Cited by 44
“3 As a result, the demand for localized antigen-spe-ci fi c immunomodulatory strategies has never been more urgent.”
Heidari, A. (2020) · Advanced Science Engineering and Medicine · doi:10.1166/asem.2020.2635 · Cited by 38
Kanbay, M., Güldan, M., Özbek, L., Çöpür, S., Covic, A. S., & Covic, A. C. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.07.014 · Cited by 42
Metabolic complications in liver transplantation recipients: how we can optimize long-term survival
Azhie, A., Sheth, P., Hammad, A., Woo, M., & Bhat, M. (2021) · Liver Transplantation · doi:10.1002/lt.26219 · Cited by 34
Carminatti, M., Junior, H. T. S., Fernandes, N. M. D. S., & Sanders‐Pinheiro, H. (2018) · Nephrology · doi:10.1111/nep.13483 · Cited by 38
“5%.(37) Special attention must be given to micro- and macrovascular complications, including regular ophthalmological follow-up and periodic complete cardiovascular checkups, as PTDM increases the mortality risk two-fold, with greater impact among KTR younger than 55 years old (Table 1).”
BackgroundInfluentialDiabetes and Cardiovascular Risk in Renal Transplant Patients
Rysz, J., Franczyk, B., Radek, M., Ciałkowska-Rysz, A. D., & Gluba-Brzózka, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073422 · Cited by 42
New insights into anti-diabetes effects and molecular mechanisms of dietary saponins
Zhou, Y., & Xu, B. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2101425 · Cited by 41
“Currently, the traditional strategies found in the market for DM and its complications managements primarily consist of biodegradable or chemical drugs, such as thiazo-lidinediones, metformin, and sulfonylureas (Shivaswamy, Boerner, and Larsen 2016).”
BackgroundObesity and bariatric intervention in patients with chronic renal disease
Bellini, M. I., Paoletti, F., & Herbert, P. E. (2019) · Journal of International Medical Research · doi:10.1177/0300060519843755 · Cited by 35
Clinical relevance of plasma virome dynamics in liver transplant recipients
Thijssen, M., Tacke, F., Beller, L., Deboutte, W., Yinda, K. C., Nevens, F., Laleman, W., Ranst, M. A. V., & Pourkarim, M. R. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103009 · Cited by 36
“In this study, we analysed Anelloviridae kinetics in patients with or without NO-TIID.”
BackgroundInfluentialManagement of diabetes mellitus in patients undergoing liver transplantation
Grancini, V., Resi, V., Palmieri, E., Pugliese, G., & Orsi, E. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.042 · Cited by 36
Kanbay, M., Çöpür, S., Topçu, A. U., Güldan, M., Özbek, L., Gaipov, A., Ferro, C. J., Cozzolino, M. G., Cherney, D. Z. I., & Tuttle, K. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15575 · Cited by 36
“19”
Axelrod, D. A., Cheungpasitporn, W., Bunnapradist, S., Schnitzler, M. A., Xiao, H., McAdams‐DeMarco, M., Çalışkan, Y., Bae, S., Ahn, J. B., Segev, D. L., et al. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2021.08.012 · Cited by 33
“(1) Triple maintenance (tacrolimus + mycophenolic acid/ azathioprine + prednisone), after T-cell–depleting induction: antithymocyte globulin (TMG) or alemtuzumab (ALEM) (reference) (2) Triple maintenance after IL-2 receptor antibody (IL2rAb): IL2rAb + triple therapy (3) Steroid avoidance/withdrawal after T-cell–deplet…”
BackgroundSiren, E. M. J., Luo, H. D., Tam, F. F., Montgomery, A., Enns, W., Moon, H., Sim, L., Rey, K., Guan, Q., Wang, J.-J., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00777-y · Cited by 38
Rivinius, R., Gralla, C., Helmschrott, M., Darche, F. F., Ehlermann, P., Bruckner, T., Sommer, W., Warnecke, G., Kopf, S., Szendroedi, J., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.890359 · Cited by 33
Saravanan, P. B., Kalivarathan, J., Khan, F., Shah, R., Levy, M. F., & Kanak, M. A. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121722 · Cited by 30
Cardiovascular Risk after Kidney Transplantation: Causes and Current Approaches to a Relevant Burden
Reggiani, F., Moroni, G. L., & Ponticelli, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12081200 · Cited by 33
“It is safer to obtain acceptable glucose levels rather than insist on “ideal” lower glucose levels [11].”
BackgroundQu, C., Tan, X., Hu, Q., Tang, J., Wang, Y., He, C., He, Z., Li, B., Fu, X., & Du, Q. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26863 · Cited by 32
“Furthermore, DM is regarded as the third major noncommunicable disease after cardiovascular disease and cancer [4], and its complications seriously affect the quality of life of patients and can even threaten life [5,6].”
BackgroundLi, L., Zhao, H., Chen, B., Fan, Z., Li, N., Yue, J., & Ye, Q. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-02170-5 · Cited by 28
RetractedKiser, J. D., & Cantrell, G. K. (2006) · Supply chain management review · Cited by 41
Posttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia
Munoz Pena, J. M., & Cusi, K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad395 · Cited by 24
Early Post-Renal Transplant Hyperglycemia
Iqbal, A., Zhou, K., Kashyap, S. R., & Lansang, M. C. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab697 · Cited by 32
Ko, E. J., Shin, Y., Cui, S., Lim, S. W., Chung, B. H., & Yang, C. W. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17035 · Cited by 25
Posttransplantation Diabetes Mellitus Among Solid Organ Recipients in a Danish Cohort
dos Santos, Q., Hornum, M., Terrones‐Campos, C., Crone, C. G., Wareham, N. E., Søborg, A., Rasmussen, A., Gustafsson, F., Perch, M., Soerensen, S. S., et al. (2022) · Transplant International · doi:10.3389/ti.2022.10352 · Cited by 32
Long Term Complications of Immunosuppression Post Liver Transplant
Mehtani, R., & Saigal, S. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.06.007 · Cited by 27
Berković, M. C., Virović-Jukić, L., Bilić-Čurčić, I., & Mrzljak, A. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i21.2740 · Cited by 25
Ertuğlu, L. A., Porrini, E., Hornum, M., Demiray, A., Afşar, B., Ortíz, A., Covic, A. C., Rossing, P. R., & Kanbay, M. (2021) · Transplant International · doi:10.1111/tri.13883 · Cited by 26
“with increased morbidity and mortality [3].”
BackgroundPost-transplant diabetes mellitus: incidence, predicting factors and outcomes
Mizrahi, N., Braun, M., Gal, T. B., Rosengarten, D., Kramer, M. R., & Grossman, A. (2020) · Endocrine · doi:10.1007/s12020-020-02339-9 · Cited by 25
Utility of HbA1c assessment in people with diabetes awaiting liver transplantation
Bhattacharjee, D., Vracar, S., ROUND, R. A., Nightingale, P., Williams, J. A., Gkoutos, G. V., STRATTON, I. M., Parker, R., Luzio, S. D., Webber, J., et al. (2018) · Diabetic Medicine · doi:10.1111/dme.13870 · Cited by 22
Paek, J. H., Kang, S. S., Park, W. Y., Jin, K., Park, S. B., Han, S., Kim, C., Ro, H., Lee, S., Jung, C. W., et al. (2019) · Transplantation Proceedings · doi:10.1016/j.transproceed.2019.02.054 · Cited by 22
Risk assessment and management of post-transplant diabetes mellitus
Han, E., Kim, M. S., Kim, Y. S., & Kang, E. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.07.011 · Cited by 30
“glucose <180 mg/dL for other patients [98].”
BackgroundInfluentialSimonenko, M., Hansen, D., Niebauer, J., Volterrani, M., Adamopoulos, S. N., Amarelli, C., Ambrosetti, M., Anker, S. D., Bayés‐Genís, A., Gal, T. B., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae179 · Cited by 35
Londero, T. M., Giaretta, L. S., Farenzena, L. P., Manfro, R. C., Canani, L. H. S., Lavinsky, D., Leitão, C. B., & Bauer, A. C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01521 · Cited by 22
“The PTDM prevalence increases in proportion to the number of transplantations performed, varying from 10% to 74% in a series of kidney transplants (3).”
BackgroundYeh, H., Lin, C., Li, Y., Yen, C., Lee, C., Chen, J., Chen, K., Tian, Y.-C., Liu, P., & Hsiao, C.-C. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00541-3 · Cited by 24
“The possible explanations of higher DM occurrence include the use of immunosuppressive agents as well as the insulin resistance caused by inflammation and infection after transplantation [16, 19].”
BackgroundQin, L., Chen, D., Xie, L., Yu, Q., Chen, Y., & Xie, J. (2022) · Process Biochemistry · doi:10.1016/j.procbio.2022.07.014 · Cited by 21
Li, P., Zhang, R., Zhou, J., Guo, P., Liu, Y., & Shi, S. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2310277 · Cited by 22
Xu, J., Xu, L., Wei, X., Li, X., & Cai, M. (2018) · Transplantation Proceedings · doi:10.1016/j.transproceed.2018.08.007 · Cited by 19
Immunosuppression following organ transplantation. Part 2: complications and their management
Cajanding, R. J. M. (2018) · British Journal of Nursing · doi:10.12968/bjon.2018.27.18.1059 · Cited by 23
Demir, B., & Bülbüloğlu, S. (2021) · Transplant Immunology · doi:10.1016/j.trim.2021.101468 · Cited by 21
Cheng, C.-Y., Chen, C.-H., Wu, M.-F., Wu, M.-J., Chen, J.-P., Liu, Y.-M., Hou, Y.-C., & Wang, H.-Y. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17124581 · Cited by 18
“Although studies had shown that the major causes of death in patients with PTDM are related to cardiovascular disease [30,31], the use of immunosuppressants after kidney transplantation can allow severe infection and even death in patients with PTDM [32].”
BackgroundImmunosuppressive drugs and associated complications in abdominal organ transplantation
Olson, J. C. (2022) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000927 · Cited by 18
“insulin resistance and stimulation of hepatic gluconeogenesis [49].”
BackgroundA mixed blessing for liver transplantation patients — Rapamycin
Fan, G.-H., Zhang, C.-Z., Gao, F., Wei, X., Ling, S., Wang, K., Wang, J., Zheng, S., Nikfarjam, M., & Xu, X. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.10.004 · Cited by 19
Role of sex in post-transplant diabetes mellitus development: Are men and women equal?
Dedinská, I., Graňák, K., Vnučák, M., Skálová, P., Kováčiková, L., Laca, Ľ., Miklušica, J., Prídavková, D., Galajda, P., & Mokáň, M. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.12.017 · Cited by 24
Cheng, F., Li, Q., Wang, J., Zeng, F., & Zhang, Y. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13493 · Cited by 18
Cystic fibrosis-related diabetes: optimizing care with a multidisciplinary approach
Frost, F. J., Dyce, P., Ochota, A., Pandya, S., Clarke, T., Walshaw, M. J., & Nazareth, D. S. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s180597 · Cited by 21
“Screening is also particularly important in people with CF who have received solid organ transplantation as posttransplant diabetes mellitus is common and can be independently associated with increased infections and mortality.(39)”
BackgroundDiabetes in Kidney Transplantation
Cantarin, M. P. M. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.10.004 · Cited by 19
Impact of diabetes mellitus on clinical outcomes after heart transplantation
Feng, K. Y., Henricksen, E. J., Wayda, B. J., Moayedi, Y., Lee, R., Han, J., Multani, A., Yang, W., Purewal, S., Puing, A. G., et al. (2021) · Clinical Transplantation · doi:10.1111/ctr.14460 · Cited by 17
Obesity affects graft function but not graft loss in kidney transplant recipients
Bellini, M. I., Koutroutsos, K., Nananpragasam, H., Deurloo, E. K., Galliford, J. W., & Herbert, P. E. (2020) · Journal of International Medical Research · doi:10.1177/0300060519895139 · Cited by 16
“This might contribute to ameliorating the outcome in the high-BMI population because in fact there is no difference in the incidence of post-transplant diabetes (Table 2), given that obesity is associated with an increased risk of steroid-induced diabetes.(20) In our view, a possible way forward would be the use of ne…”
BackgroundEndocrine effects of long-term calcineurin inhibitor use in solid organ transplant recipients
Diker‐Cohen, T., Dotan, I., Calvarysky, B., & Robenshtok, E. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf182 · Cited by 19
Tsai, S., & Chen, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133152 · Cited by 16
“The incidence of NODAT varied (10% to 74%) [42] according to the different times of diagnosis after transplantation, different definitions, different immunosuppressants and different patient demographics.”
BackgroundMicrobiota-dependent and -independent effects of obesity on transplant rejection and hyperglycemia
Li, Z., Chen, L., Sepulveda, M., Wang, P., Rasic, M., Tullius, S. G., Perkins, D. L., & Alegre, M. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.06.011 · Cited by 20
Post-transplant diabetes mellitus: risk factors and outcomes in a 5-year follow-up
Rossi, M. R., Mazzali, M., & de Sousa, M. V. (2024) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2024.1336896 · Cited by 21
“The PTDM management after hospital discharge include oral hypoglycemic drugs alone or associated with insulin (25).”
BackgroundInfluentialRudzki, G., Knop-Chodyła, K., Piasecka, Z., Kochanowska-Mazurek, A., Głaz, A., Wesołek, E., & Woźniak, M. M. (2024) · Pharmaceuticals · doi:10.3390/ph17080987 · Cited by 20
“In patients with end-stage renal disease, kidney transplantation is the most effective and preferred form of treatment, improving the survival of these patients [1].”
BackgroundPrevention of Post-Transplant Diabetes Mellitus: Towards a Personalized Approach
Ducloux, D., & Courivaud, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010116 · Cited by 20
“Furthermore, mTORi favors beta-cell apoptosis [99].”
Genetic factors in pathogenesis of diabetes mellitus after kidney transplantation
Tarnowski, M., Słuczanowska-Głąbowska, S., Pawlik, A., Mazurek−Mochol, M., & Dembowska, E. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s129327 · Cited by 17
“For 14–16 CNIs, such as cyclosporine and tacrolimus, also are diabetogenic.”
Ahn, J. B., Bae, S., Schnitzler, M. A., Hess, G. P., Lentine, K. L., Segev, D. L., & McAdams‐DeMarco, M. (2021) · Transplantation Direct · doi:10.1097/txd.0000000000001260 · Cited by 17
Metadata
- Authors
- Shivaswamy, V., Boerner, B., & Larsen, J.
- Affiliations
- VA Nebraska Western Iowa Health Care System (US)
- University of Nebraska Medical Center (US)
- Corresponding author
- Larsen, Jennifer
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2015-12-09
- Volume
- 37
- Issue
- 1
- Pages
- 37-61
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC4740345
- OpenAlex
- W2190934800
- Cited by
- 328
- References
- 230
- Citations by year
- 2026: 30 · 2025: 36 · 2024: 35 · 2023: 31 · 2022: 32 · 2021: 44 · 2020: 51 · 2019: 29 · 2018: 30 · 2017: 5 · 2016: 4
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Reviews (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Office of Research and Development
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- post-transplant diabetes mellitus, solid organ transplantation, immunosuppression, corticosteroids, impaired glucose tolerance, diabetes screening, HbA1c, type 2 diabetes risk factors, drug-drug interactions, hypoglycemia, graft survival, mortality, infection risk, diabetes treatment
- MeSH terms
- Adrenal Cortex Hormones, Animals, Combined Modality Therapy, Diabetes Mellitus, Graft Rejection, Graft Survival, Humans, Immunosuppressive Agents, Postoperative Complications, Risk Factors, Stress, Physiological, Organ Transplantation, Cost of Illness, Practice Guidelines as Topic, Evidence-Based Medicine, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.